Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Malignant Lymphoma

  Free Subscription


13.10.2025

3 Blood
6 Br J Haematol
1 Cancer Res
2 Haematologica
1 Hum Pathol
1 Int J Cancer
1 J Clin Oncol
1 J Natl Cancer Inst
3 Leuk Lymphoma
1 Leukemia
1 Mod Pathol
1 Oncogene


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Blood

  1. VARDHANA SA
    Smarter combos, stronger T cells in lymphoma.
    Blood. 2025;146:1742-1744.
    PubMed        

  2. ARMAND P
    Introduction to a review series on follicular lymphoma: solved or insoluble problem?
    Blood. 2025;146:1739-1740.
    PubMed        

  3. SHI M, Rech KL
    T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
    Blood. 2025;146:1868.
    PubMed        


    Br J Haematol

  4. LYNCH RC, Cassaday RD, Smith SD, Cowan AJ, et al
    Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphoma.
    Br J Haematol. 2025;207:1599-1603.
    PubMed         Abstract available

  5. WU R, Li Y, Zhang D, Liu T, et al
    Population pharmacokinetics of high-dose methotrexate and 7-hydroxy methotrexate in Chinese adults with primary central nervous system lymphoma.
    Br J Haematol. 2025;207:1622-1627.
    PubMed        

  6. MARTINEZ ALCALA R, Lei Y, Visser L, Diepstra A, et al
    Programmed cell death-1 inhibition activates CD4 T cells in a novel in vitro model of Hodgkin lymphoma.
    Br J Haematol. 2025;207:1643-1647.
    PubMed        

  7. TRIANTAFILO N, Chowdhury A, Thiruvengadam S, Herrera AF, et al
    Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma.
    Br J Haematol. 2025;207:1668-1672.
    PubMed        

  8. MUNZ N, Arribas AJ, Bordone Pittau R, Simonetta F, et al
    Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphoma.
    Br J Haematol. 2025 Oct 7. doi: 10.1111/bjh.70185.
    PubMed        

  9. HU X, Li L, Nkwocha J, Vasiyani H, et al
    Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.
    Br J Haematol. 2025 Oct 5. doi: 10.1111/bjh.70188.
    PubMed         Abstract available


    Cancer Res

  10. GUREVICH-SHAPIRO A, Zwicky P, Winter E, Zada M, et al
    Distinct cellular and molecular patterns in pre-treatment peripheral blood are associated with CAR-T cell outcomes in diffuse large B-cell lymphoma.
    Cancer Res. 2025 Oct 10. doi: 10.1158/0008-5472.CAN-25-3596.
    PubMed         Abstract available


    Haematologica

  11. SENTHIL H, Streilein S, Whiteside T, Minuk L, et al
    Real-world safety and tolerability of rapid infusion obinutuzumab in chronic lymphocytic leukemia, small lymphocytic lymphoma and non-Hodgkin lymphoma: a provincial review.
    Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288780.
    PubMed         Abstract available

  12. MARR KC, Tang T, Simkin J, Kim J, et al
    Long-term cardiac morbidity in adolescent and young adult survivors of classical Hodgkin lymphoma: the British Columbia experience.
    Haematologica. 2025 Oct 9. doi: 10.3324/haematol.2025.288058.
    PubMed         Abstract available


    Hum Pathol

  13. SEKHRI R, Tian X, Chai J, Malik P, et al
    Interdisciplinary analysis of cues to triage gastric lymphoid proliferations: Role of the surgical pathologist revisited.
    Hum Pathol. 2025;164:105931.
    PubMed         Abstract available


    Int J Cancer

  14. QIU L, Bai S, Cai J, Fang Y, et al
    Antiviral prophylaxis for hepatitis B virus reactivation in T-cell lymphoma patients with resolved hepatitis B virus infection.
    Int J Cancer. 2025 Oct 4. doi: 10.1002/ijc.70186.
    PubMed         Abstract available


    J Clin Oncol

  15. ROSSI D
    Assessing Remission in Diffuse Large B-Cell Lymphoma: Will Minimal Residual Disease Add Value to Positron Emission Tomography?
    J Clin Oncol. 2025 Oct 7:JCO2501932. doi: 10.1200/JCO-25-01932.
    PubMed        


    J Natl Cancer Inst

  16. CHOKUNONGA E, Makunike-Mutasa R, Borok M, Chirenje MZ, et al
    Trends in the incidence of cancers related to HIV-AIDS in Harare, Zimbabwe 1990-2019.
    J Natl Cancer Inst. 2025;117:2096-2102.
    PubMed         Abstract available


    Leuk Lymphoma

  17. GUPTA S, Bachanova V
    CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma: lessons learned from clinical trials and real world evidence.
    Leuk Lymphoma. 2025 Oct 10:1-13. doi: 10.1080/10428194.2025.2560082.
    PubMed         Abstract available

  18. SAKUMA H, Narita K, Tabata R, Fujii F, et al
    Clinical and radiological prediction models for random skin biopsy positivity in suspected intravascular large B-cell lymphoma: development and internal validation.
    Leuk Lymphoma. 2025 Oct 8:1-8. doi: 10.1080/10428194.2025.2568742.
    PubMed         Abstract available

  19. WATRIN T, Seifert M, Dietrich S
    The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
    Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
    PubMed         Abstract available


    Leukemia

  20. VALLOIS D, Missiaglia E, Veloza L, Fischer A, et al
    Divergent molecular pathways drive monomorphic epitheliotropic and enteropathy-associated intestinal T-cell lymphoma.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02777.
    PubMed         Abstract available


    Mod Pathol

  21. FISCHER GM, Tsai HK, Huang J, Mochel MC, et al
    Genomic profiling of pediatric mycosis fungoides, lymphomatoid papulosis z, and primary cutaneous anaplastic large cell lymphoma identifies recurrent tyrosine kinase gene fusions.
    Mod Pathol. 2025 Oct 8:100908. doi: 10.1016/j.modpat.2025.100908.
    PubMed         Abstract available


    Oncogene

  22. CLEMENS MJ, Bushell M, Morley SJ
    Correction to: Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines.
    Oncogene. 2025 Oct 8. doi: 10.1038/s41388-025-03586.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.